Eutropoflavin

4'-DMA-7,8-DHF (4'-dimethylamino-7,8-dihydroxyflavone) is a synthetic flavone derivative developed as a more potent analog of 7,8-dihydroxyflavone (7,8-DHF), a small molecule identified as a selective agonist of the tropomyosin-related kinase B (TrkB) receptor, the primary receptor for brain-derived neurotrophic factor (BDNF) ^[2]. It was first described in a 2010 medicinal-chemistry optimization of the 7,8-DHF scaffold, where adding a dimethylamino substituent at the 4' position of the pendant phenyl ring produced a compound that displayed higher TrkB agonistic activity than the lead and a more robust, longer-lasting TrkB activation in animals ^[1]. Because it engages the same receptor as BDNF, it is often described as a "BDNF-mimetic," and it is sold by some supplement vendors under the marketing name Eutropoflavin.

In the founding study, 4'-DMA-7,8-DHF triggered TrkB phosphorylation at lower concentrations than 7,8-DHF (reported in the low-nanomolar range versus roughly ten-fold higher for the parent), and chronic oral administration in mice strongly promoted neurogenesis in the dentate gyrus of the hippocampus while producing marked antidepressant-like effects in the forced swim and tail suspension tests ^[1]. Both compounds were characterized as orally bioavailable TrkB agonists, which is much of the appeal relative to BDNF itself, a protein that does not cross the blood-brain barrier and is unusable as an oral drug ^[1][2]. The downstream signaling recruited by TrkB activation includes the Akt, ERK/MAPK, and CREB pathways associated with neuronal survival and synaptic plasticity ^[2].

The parent scaffold is a catechol, which brings pharmacokinetic liabilities: catechol-containing molecules are subject to rapid conjugation and O-methylation, giving them short systemic exposure. A follow-up optimization campaign explicitly set out to improve the poor pharmacokinetic profile intrinsic to these catechol-containing agonists while preserving TrkB activity, ultimately moving away from the labile dimethylamino group toward bioisosteric replacements ^[3]. Separately, work on 7,8-DHF metabolism showed that its O-methylated metabolites themselves activate TrkB and carry antidepressant activity, and that blocking methylation with COMT inhibitors reduces the TrkB response, complicating any simple reading of what the administered molecule does in the body ^[4]. A 2023 rodent pharmacokinetic comparison measured plasma and brain levels of both 7,8-DHF and 4'-DMA-7,8-DHF after intraperitoneal dosing in rats and found the parent to be the more metabolically stable of the two at systemic exposure, tempering the marketing framing of 4'-DMA-7,8-DHF as simply the "more bioavailable" option ^[5].

Overall, the evidence for 4'-DMA-7,8-DHF is entirely preclinical; the data come from cell assays and rodent models of depression and neurogenesis, and no controlled human trials have been reported for the compound itself. Human safety, effective oral dose, and long-term effects are uncharacterized. It is best understood as a research compound and an experimental TrkB tool rather than an established supplement or drug.

no human safety data exists for 4'-DMA-7,8-DHF; it has never been through a clinical trial. Everything known comes from cell and rodent studies, so its side-effect profile, safe dose, drug interactions, and long-term effects in people are all unknown. It is a research compound, not an approved drug or a well-characterized supplement, and any use is experimental. Chronic TrkB activation is not a fully benign target on paper; growth-factor signaling has theoretical proliferation concerns, and the compound's demethylation and catechol metabolism add uncertainty. People who are pregnant, nursing, on psychiatric or other medications, or who have any medical condition should not use it. Treat unverified vendor purity claims with skepticism.

Eutropoflavin, chemically 4'-dimethylamino-7,8-dihydroxyflavone (4'-DMA-7,8-DHF), is a synthetic flavone created through structural modification of tropoflavin (7,8-dihydroxyflavone), a small-molecule TrkB agonist reported by academic medicinal chemists in the late 2000s and 2010s. Investigators added a dimethylamino group at the 4' position to increase potency at the BDNF receptor TrkB and to lengthen the duration of action in rodents. The compound has no approved medical indication and reached the public largely through the research-chemical and nootropic supplement market rather than through formal pharmaceutical development.

Eutropoflavin is regarded by enthusiasts as a promising next-generation BDNF mimetic, promoted for neurogenesis, mood, and cognitive resilience on the strength of its improved potency and half-life relative to 7,8-dihydroxyflavone, and vendor and community writeups are generally favorable. More cautious researchers and users emphasize that essentially all supporting data are preclinical, that no human trials or long-term safety studies exist, and that its status as an unregulated research-grade material means current enthusiasm outpaces the available evidence.